In a 10 L baffled reactor equipped with a 4-blade pitched turbine impeller, the long-acting injectable microsphere veterinary-grade API is manufactured into PLGA-based microsphere depots for companion animal parenteral administration via an oil-in-water (O/W) solvent extraction/quenching sequence. The organic phase containing the API and PLGA 50:50 RG 503H at a feed ratio of 1:3.3 (API:polymer by mass) in dichloromethane at 18–22% w/v total solids is dispersed into a 0.5–1.5% w/v polyvinyl alcohol continuous phase at 500–700 rpm. Solvent evaporation kinetics are controlled by maintaining the reactor jacket at 18–20 °C and sparging nitrogen at 0.5–1.0 L/min to reduce dichloromethane partial pressure; API entrainment on baffle surfaces is a common yield loss observed on 10 L glass reactors, with mass balance recoveries dropping to 68–75% when the surface-to-volume ratio exceeds 1.2 cm⁻¹. The resulting droplets are hardened by solvent exchange into 2.5–4 L of 1.0% w/v PVA extraction water for 4–6 h. Collected microspheres are washed with water for injection and lyophilized at primary drying shelf temperature −25 °C and secondary drying +20 °C for 18–24 h to reach residual moisture ≤ 2.0 wt%. Particle size is measured by laser diffraction as Dv50 35–65 µm and span below 1.4. The final drug loading is targeted at 12–18 wt%, with encapsulation efficiency 70–85% for hydrophobic actives; published data for this specific configuration is limited for highly water-soluble actives, where burst release may exceed 30% unless a double-emulsion water-in-oil-in-water (W/O/W) route is used. The terminal article is a sterile lyophilized microsphere cake for reconstitution into a suspension for subcutaneous injection, typically sieved through a 125 µm screen and filled into Type I glass vials under aseptic conditions. Compliance for subvisible particulate matter follows USP 788 and Ph. Eur. 2.9.19; residual dichloromethane is controlled to ≤ 600 ppm and total residual solvents to VICH GL18 limits; sterility testing follows USP 71 and bacterial endotoxin limits are set at ≤ 0.5 EU/mg according to USP 85 for companion animal parenterals.

What Converts a Microsphere-Grade API into a Segregation-Resistant Swine Premix Granule?

When the final premix must be included at 2–5 wt% of the complete feed and achieve a relative standard deviation below 5.0% in a 10-sample mixer batch validation, segregation-resistant granulation for swine medicated feed is specified. The primary failure mode is assay drift caused by particle size mismatch between the micronized API and limestone or rice hull carriers. The API is first pre-blended with colloidal silicon dioxide at 0.5–1.0 wt% of the premix to reduce agglomeration, then incorporated into a ribbon mixer at 25–50 g/kg active concentration. Blender fill level is kept at 50–70% and mixing time at 15–20 min; early discharge before 10 min produces assay RSD above 8% in field samples. The blend is transferred to a fluid-bed granulator with inlet air 55–65 °C, bed temperature 30–35 °C, and spray rate 150–250 g/min for a hydroxypropyl methylcellulose binder solution at 5–7% w/w of dry mass. Granules are sieved to 150–850 µm and final dried to moisture ≤ 4.0 wt%. The terminal product type is a low-dust medicated premix or granulate for on-farm mixing into complete swine rations; this is distinct from a microsphere depot because the release mechanism is matrix hydration and erosion in the gastrointestinal tract rather than parenteral polymer degradation. Regulatory anchors include FDA 21 CFR 558.3 and 558.4 for medicated feed mill licensing, EU Regulation 2019/4 and associated homogeneity requirements under Regulation 2020/354, and VICH GL9 for good manufacturing practice. Published data for this specific configuration is limited where the API is a high-potency microsphere-grade active with log P above 4.5; wet granulation with ethanolic binder should then be replaced by aqueous binder to avoid solvent residue concerns unless a dedicated solvent recovery dryer is available.

When Feed Withdrawal Restricts Oral Dosing, Water-Soluble Granules Replace Premix Carriers

For drinking water medication in poultry, the microsphere-grade API is required to dissolve completely within 5 min at 20–25 °C water and not precipitate over 24 h at pH 6.5–8.0. The addition ratio in the final drinking water is typically 0.05–0.50 g/L active, corresponding to a 5–50 ppm dose-equivalent concentration, while the dry powder intermediate contains 10–25 wt% API on a mannitol–citrate–sodium bicarbonate carrier. A fluid-bed spray granulation process is used: mannitol and API are pre-mixed, then sprayed with an ethanolic or hydroalcoholic solution of polyvinylpyrrolidone K30 at 3–5 wt% binder solids, with product temperature 28–32 °C and final drying to moisture ≤ 2.0 wt%. Concentrate stability is monitored by moisture gain in opened sachets; at 65% RH, caking occurs within 48 h unless aluminum foil laminate packaging with desiccant is used. For hard water above 300 mg/L as CaCO₃, the formulation includes 2–4 wt% sodium tripolyphosphate or citric acid at a 1:1 molar ratio to chelate divalent cations and prevent insoluble API–calcium complexes. The terminal finished product type is a sachet-filled water-soluble powder or effervescent granule for in-line medication through pesticide-free drinking lines. Compliance follows Ph. Eur. 2.9.5 for uniformity of mass, Ph. Eur. 5.17.1 or 5.17.2 dosage form recommendations, and residual solvent limits under VICH GL18. Water solubility testing at 5× and 10× the target concentration against an internal specification is required because precipitation in nipple drinkers is the most common field failure; published data for this specific configuration is limited below pH 5.5, where acid-sensitive actives may degrade faster than 10% in 4 h.

Because ruminal pH and mechanical contractions differ sharply from human gastrointestinal conditions, oral tablets for cattle and calves rarely behave like immediate-release forms. The ruminal environment maintains a pH range of 5.5–7.0 and mechanical contractions above 0.1 N/cm² over hours. The microsphere-grade API is incorporated at 12.5–25 wt% of the tablet core for high-dose anthelmintic or anti-anaplasmosis regimens, with microcrystalline cellulose and ethylcellulose 7FP as a matrix former. Direct compression is run on a rotary tablet press with a compression force of 15–25 kN, turret speed 20–35 rpm, and tablet hardness targeted at 100–200 N to minimize ruminal disintegration. Compression dwell time 35–80 ms influences tablet porosity; tablets with porosity below 10% show capping when exposed to ruminal pH. When the API is poorly compressible, wet granulation in a high-shear mixer at impeller 300–400 rpm and chopper 1800–2500 rpm is used with a 6–8 wt% starch paste binder; the granules are dried at 50–55 °C to loss-on-drying ≤ 3.0 wt%, then lubricated with magnesium stearate at 0.75–1.25 wt%. The terminal finished product type is an oral tablet or two-piece hard gelatin capsule, usually film-coated with ethylcellulose or hydroxypropyl methylcellulose to provide delayed erosion in the reticulum. Compliance anchors include Ph. Eur. 2.9.3 disintegration testing, USP 711 dissolution, and Ph. Eur. 2.9.40 content uniformity; residual solvent limits follow VICH GL18. Because ruminal retention time variation can exceed 18 h, dissolution profiles should be generated at pH 5.5, 6.2, and 7.0 rather than a single compendial medium.

Non-Aqueous Depot Suspensions for Bovine Injection Are Not Equivalent to PLGA Microspheres

If a 7–14 day release window is sufficient and PLGA microsphere cost or terminal sterilization constraints apply, cattle and sheep injectable depots are formulated as sterile non-aqueous suspensions in medium-chain triglyceride or ethyl oleate instead of PLGA microspheres. The addition ratio is 5–15 wt% API in the final suspension, with a wetting agent such as polysorbate 80 at 0.5–1.0 wt% and a thixotropic agent such as aluminum monostearate at 1.0–2.0 wt% to control sedimentation. Viscosity at 20 °C is adjusted to 80–150 mPa·s at 10 s⁻¹ to maintain syringeability through 18G needles; aluminum monostearate gelation temperature 35–45 °C is avoided during bead milling. The downstream process is wet bead milling on a recirculating mill with 0.3 mm yttria-stabilized zirconia beads to achieve a particle size d90 ≤ 20 µm, followed by filtration through 5 µm and 0.2 µm cartridge filters for bioburden reduction because terminal sterile filtration of a suspension is not feasible. Sterilization is performed by gamma irradiation at 25 kGy or by dry-heat sterilization of the milled powder and aseptic compounding in a filling isolator. The terminal finished product type is a ready-to-use injectable suspension in Type I glass vials or cyclic olefin copolymer syringes. Compliance for injectable particulate matter follows USP 788; sterility follows USP 71; endotoxin limit is ≤ 0.5 EU/mg; extractables testing follows USP 661.1 for plastic packaging systems. This route differs from microsphere depots because drug release is controlled by dissolution of suspended particles and particle-size-dependent settling rather than by polymer degradation; published data for this specific configuration is limited for highly sedimenting actives with specific gravity above 1.6.

To hold drug recovery above 90% during extrusion, aquaculture feed mills compound the microsphere-grade API into sinking or floating medicated pellets via a premix powder that must withstand extrusion temperatures 85–105 °C and high shear inside a twin-screw extruder with L/D ratio 24:1–32:1. The addition ratio in final feed is 5–25 g/kg depending on species, while the premix intermediate is typically 50–200 g/kg API on a corn starch and zeolite carrier. A cold granulation or granulated premix is produced by low-temperature fluid-bed agglomeration at 35–45 °C to avoid degradation before extrusion; the granules are sieved to 100–500 µm so they distribute homogeneously through the feed mash and survive the preconditioning step at 90–95 °C for 45–90 s. Post-extrusion vacuum coating at 60–70 °C drying for 30–60 min reduces drug degradation compared with pre-extrusion mixing. The terminal finished product type is a medicated extruded pellet or sinking granule for oral administration in finfish or shrimp; for shrimp, pellet size 1.2–2.0 mm is common, while for salmonid smolt feeds 2.0–3.5 mm pellets are used. Compliance for residues in aquaculture species follows EU Regulation 37/2010 maximum residue limits and Codex Alimentarius guidelines; feed additive use is controlled under EU 1831/2003 or FDA 21 CFR 558; homogeneity must meet relative standard deviation ≤ 5% per EU 2020/354. Published data for this specific configuration is limited where the API is heat-labile with degradation threshold below 70 °C; in that case the medicated premix must be applied post-extrusion by vacuum coating rather than pre-extrusion mixing.